NLA 2016:他汀类药物和心血管药物间的相互作用研究

2016-05-22 Seven L 译 MedSci原创

国家脂质协会科学会议上有专家称,许多心血管药物会与他汀类药物相互作用,因此临床医生必须了解这些关系的大小,以确保这些药物对患者没有损害。南卡罗来纳药学院副教授、南卡罗莱纳医科大学心脏病学的专家Barbara S. Wiggins博士对他汀类药物与其他心血管药物之间的相互作用程度进行了探讨,根据AUC值定义相互作用程度:1.2-2 轻度;>2-4.9 中度;≥5 重度。目前已经知道贝特类会和他汀类药

国家脂质协会科学会议上有专家称,许多心血管药物会与他汀类药物相互作用,因此临床医生必须了解这些关系的大小,以确保这些药物对患者没有损害。

南卡罗来纳药学院副教授、南卡罗莱纳医科大学心脏病学的专家Barbara S. Wiggins博士对他汀类药物与其他心血管药物之间的相互作用程度进行了探讨,根据AUC值定义相互作用程度:1.2-2 轻度;>2-4.9 中度;≥5 重度。

目前已经知道贝特类会和他汀类药物发现相互作用,比如吉非贝齐抑制葡萄糖醛酸化,而他汀类药物如阿托伐他汀、氟伐他汀、洛伐他汀和辛伐他汀可以消除活性羟基的酸性代谢产物,非诺贝特没有这个问题。

烟酸和他汀类类似,会导致不良骨骼肌作用,已使用他汀类药物的患者,服用烟酸的剂量不能超过1g(也有人建议这个剂量为2g)。

钙通道阻滞剂氨氯地平、地尔硫卓、维拉帕米联合洛伐他汀和辛伐他汀,AUC增加1.76-3.7倍。

心律失常药物决奈达隆和胺碘酮(Multaq, Sanofi Aventis) 和洛伐他汀、辛伐他汀也有相互作用。

雷诺嗪(Ranexa,Gilead Sciences)与辛伐他汀有轻度相互作用,而替卡格雷(Brilinta, AstraZeneca) 和阿托伐他汀、辛伐他汀、洛伐他汀的相互作用为中度。

免疫抑制剂环孢霉素A、依维莫司、西罗莫司和他克莫司会导致各种他汀类药物AUC增加2-15倍。

目前关于两个新的房颤药物伊伐布雷定(Corlanor, Amgen) 和缬沙坦(Entresto, Novartis)与他汀类药物的相互作用知之甚少。

“我们希望能够为病人选择最佳药物,让病人得到最好的治疗。”了解认识并把握药物之间的相互作用是前提。

原始出处:


Wiggins BS. Evaluating the Landscape of Statin Drug Interactions with Select Cardiovascular Medications: What You Need to Know. Presented at: National Lipid Association Scientific Sessions; May 19-22, 2016; New Orleans.

Statins often negatively interact with other CV drugs
.Healio.May 21, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909183, encodeId=9836190918303, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 14 05:25:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044408, encodeId=33ab204440849, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jul 31 02:25:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646030, encodeId=977d16460302e, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 15:25:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88169, encodeId=23e288169d6, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:45:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471511, encodeId=80e614e151127, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 24 02:25:00 CST 2016, time=2016-05-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909183, encodeId=9836190918303, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 14 05:25:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044408, encodeId=33ab204440849, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jul 31 02:25:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646030, encodeId=977d16460302e, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 15:25:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88169, encodeId=23e288169d6, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:45:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471511, encodeId=80e614e151127, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 24 02:25:00 CST 2016, time=2016-05-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909183, encodeId=9836190918303, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 14 05:25:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044408, encodeId=33ab204440849, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jul 31 02:25:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646030, encodeId=977d16460302e, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 15:25:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88169, encodeId=23e288169d6, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:45:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471511, encodeId=80e614e151127, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 24 02:25:00 CST 2016, time=2016-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909183, encodeId=9836190918303, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 14 05:25:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044408, encodeId=33ab204440849, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jul 31 02:25:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646030, encodeId=977d16460302e, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 15:25:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88169, encodeId=23e288169d6, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:45:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471511, encodeId=80e614e151127, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 24 02:25:00 CST 2016, time=2016-05-24, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1909183, encodeId=9836190918303, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Dec 14 05:25:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044408, encodeId=33ab204440849, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sun Jul 31 02:25:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646030, encodeId=977d16460302e, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Jul 24 15:25:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88169, encodeId=23e288169d6, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:45:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471511, encodeId=80e614e151127, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 24 02:25:00 CST 2016, time=2016-05-24, status=1, ipAttribution=)]
    2016-05-24 ylz8405

相关资讯

JCEM:长期减重饮食可增加脂联素水平,改善心血管代谢风险

近期发表在J Clin Endocrinol Metab的研究称,长期减重饮食(含有各种常量营养素)干预下,会增加循环中的脂联素,进而改善腹部脂肪分布和脂肪代谢,且这些变化均是独立于体重改变的。杜兰大学肥胖研究中心的主任Lu Qi博士和同事对768名平均年龄50.7岁的超重或肥胖成年人进行了研究。为评估了长期减重饮食对脂联素的影响,以及这些改变对心血管代谢风险的影响,研究者在纳入研究、第6个月和2

这4种降糖药已被证实有心血管获益

目前降糖药物主要包括胰岛素、二甲双胍、磺脲、格列奈、噻唑烷二酮、糖苷酶抑制剂、DPP-4i、GLP-1、SGLT-2抑制剂。在上述各类降糖药中,已被随机化临床试验证实有大血管获益仅有恩格列净、吡格列酮、利拉鲁肽与索马鲁肽。 1. 恩格列净:去年8月份公布的EMPA-REG研究证实,与安慰剂组受试者相比,在常规治疗基础上加用SGLT-2抑制剂恩格列净可以显著降低复合硬终点事件发生率。目前对

NLA 2016:降低ApoC-III可减少心血管风险

国家脂质协会科学会议上的演讲称,遗传和其他证据表明,载脂蛋白C-III的升高是冠心病的危险因素,降低其水平可减少心血管事件的风险。丹麦哥本哈根大学医院临床生物化学和分子心脏病学教授、哥本哈根大学医院医学与健康科学学院教授Anne Tybjaerg-Hansen博士在演讲中说:“对载脂蛋白C-III经过47年的研究之后,对这个物质有了更进一步的认识。”先前的遗传研究已经确定,APOC3基因功能丧失的

NLA 2016:女性多吃坚果可以降低冠心病风险

女性健康研究分析显示,增加坚果摄入量,可降低冠心病(CHD)的风险,不过坚果摄入量与女性心血管疾病(CVD)死亡率间没有关系。先前的研究表明,摄入坚果可对血脂产生积极影响,进而降低冠心病风险。来自布莱根妇女医院的Tasnim Imran博士和同事对39,167名基线没有CVD的女性进行了研究,平均年龄55岁,探究坚果摄入量和CVD死亡率以及CHD间的关系。通过问卷调查获取参与者坚果摄入情况,根据医

2015年中国心血管病报告正式发布!

随着社会经济的发展,国民生活方式发生了深刻的变化。尤其是人口老龄化及城镇化进程的加速,中国心血管病危险因素流行趋势明显,导致了心血管病的发病人数持续增加。今后10年心血管病患病人数仍将快速增长。 目前,心血管病死亡占城乡居民总死亡原因的首位,农村为44.6%,城市为42.51%。心血管病的疾病负担日渐加重,已成为重大的公共卫生问题。 1 心血管病死亡情况 2014

Lancet:很多人都错了,低钠饮食的目标人群并不是全人类

先前有研究表明,尿钠排泄与心血管事件和死亡率呈U形联系,但是对于伴或不伴高血压的患者,这种联系是否会发生变化呢?就此研究者进行了一项研究,探究伴或不伴高血压时,尿钠排泄与心血管事件和全因死亡率间的联系。 在汇总分析时共纳入了133 118名参与者,其中高血压63 559人,非高血压69 559人,中位数年龄55岁(IQR 45–63),分别来自49个国家的四个大型前瞻性研究,估计了参与者24